Related Experiment Video
Updated: Aug 5, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
6.4K
Current factor IX replacement options for hemophilia B and the challenges ahead
Massimo Franchini1, Marco Zaffanello2, Daniele Focosi3
1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.
Expert Opinion on Pharmacotherapy
|March 24, 2023
Summary
Hemophilia B treatment now includes extended half-life (EHL) factor IX (FIX) products. These advancements improve patient quality of life by reducing treatment frequency and burden.
Area of Science:
- Hematology
- Pharmacology
Background:
- Hemophilia B is a congenital deficiency of coagulation factor IX (FIX).
- Current therapies involve replacing FIX using plasma-derived or recombinant products.
- Existing treatments enable patients to lead relatively normal lives.
Approach:
- This review analyzes clinical trial outcomes of current hemophilia B treatment options.
- It focuses on advancements in extended half-life (EHL) factor IX molecules.
- Literature search was conducted using PubMed without temporal restrictions.
Key Points:
- Recombinant EHL FIX products represent a significant therapeutic advancement.
- These products reduce the treatment burden for hemophilia B patients.
- Improved compliance and quality of life are key benefits.
Conclusions:
- Extended half-life factor IX products offer improved efficacy in hemophilia B management.
- Relaxed prophylactic dosing schedules are enabled by EHL FIX.
- The development of EHL FIX products enhances patient compliance and overall quality of life.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
13
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
13
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
792
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
792
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.5K
01:24Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
01:09Coagulation
7.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.2K